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Metformin has been used for nearly a century and is now the most widely prescribed oral anti-diabetic agent
worldwide. Yet howmetformin acts remains only partially understood and controversial. One key reasonmay
be that almost all previous studies were conducted with supra-pharmacological concentrations (doses) of
metformin, 10–100 times higher than maximally achievable therapeutic concentrations found in patients
with type 2 diabetes mellitus.In the early 20th century, guanidine, which
was obtained from the Galega officinalis
plant and used in Europe as a folk medi-
cine to treat diabetes, was discovered to
lower blood glucose levels. Metformin or
dimethylbiguanide was synthesized in
the 1920s and retains the glucose-
lowering effect of its parent compound,
guanidine, while reducing toxicity. Metfor-
min was first employed in Europe and
later approved by the FDA in 1994 for
the treatment of type 2 diabetes mellitus
in the U.S. Metformin is now the most
commonly prescribed oral anti-diabetic
agent worldwide and is taken by over
150 million people each year. This drug
has also received attention because
many studies have shown a reduction in
cancer incidence in patients treated with
metformin.
Metformin is not metabolized in animals
or humans and is eliminated intact
through renal excretion. The maximal
approved total daily dose of metformin
for treatment of diabetes mellitus is 2.5 g
(35 mg/kg body weight). After oral admin-
istration, metformin is absorbed into the
enterocytes through the plasma mono-
amine transporter (PMAT) and organic
cation transporter 3 (OCT3) on the apical
membrane and leaves the enterocytes
via OCT1 on the basolateral membrane
(Figure 1). Metformin is then delivered
directly to the liver through the portal
vein, and plasma concentrations in the
portal vein are between 40 and 70 mM in
animals after a therapeutic dose. The up-
take ofmetformin in the liver is through the
OCT1/3 on the membrane of hepato-
cytes, while metformin is excreted from
hepatocytes by the multidrug and toxin
extrusion 1 (MATE1) transporter. Themet-
formin uptake velocity in primary hepato-cytes follows a curvilinear relationship,
and the Km is about 220 mM, which is 3-
to 5-fold higher than metformin concen-
trations in the portal vein (Jin et al.,
2009). After hepatic uptake, the systemic
plasma concentration of metformin is
reduced to 10–40 mM in animals (Wilcock
and Bailey, 1994) and in humans. In the
kidney, metformin is absorbed from the
circulation into renal epithelial cells by
OCT2 and excreted into urine by
MATE1/2k (Gong et al., 2012). While it is
clear that metformin acts primarily to sup-
press glucose production in the liver, the
actual mechanism remains controversial.
Themajor mechanisms proposed for sup-
pression of hepatic glucose production by
metformin will be discussed in this review.
Over a decade ago, metformin was
found to activate AMPK by increasing
the net phosphorylation of the AMPK
catalytic a subunit at Thr172 in primary
hepatocytes (Zhou et al., 2001). A subse-
quent study showed that hepatic
knockout of LKB1, the upstream kinase
for AMPKa phosphorylation at Thr172,
abolished metformin suppression of he-
patic glucose production (Shaw et al.,
2005). Moreover, activation of AMPK re-
sults in the phosphorylation of CBP at
Ser436, which then leads to disassembly
of the CREB co-activator complex and
subsequent inhibition of gluconeogenic
gene expression (He et al., 2009). Inter-
estingly, this CBP phosphorylation site
does not exist in the closely related pro-
tein P300. To assess the importance of
this site in mediating suppression of he-
patic glucose production (HGP), we re-
constituted this site in mouse P300
(P300G442S knockin). These mice ex-
hibited exaggerated hypoglycemia in a
metformin tolerance test and further sup-Cell Metabolism 21port the importance of CBP phosphoryla-
tion in mediating suppression of HGP by
metformin (He et al., 2014). Importantly,
low metformin concentrations (%50 mM)
activate AMPK activity, and these con-
centrations are within the range of metfor-
min concentrations found in the portal
vein (Zhou et al., 2001). Our recent study
confirmed that low metformin concentra-
tions (%80 mM) activated AMPK activity,
increased the net phosphorylation of
AMPKa subunit at Thr172, and led to the
phosphorylation of CBP (Cao et al.,
2014; He et al., 2014). Furthermore, low
metformin concentrations suppressed di-
butyryl-cAMP-stimulated gluconeogenic
gene expression and glucose produc-
tion in primary hepatocytes. In parallel
studies, depletion of AMPK catalytic
subunits abolished the suppression of di-
butyryl-cAMP-stimulated glucose pro-
duction by low metformin concentrations
(Cao et al., 2014). The above findings
support a mechanism for metformin sup-
pression of HGP via activation of the
LKB-AMPK pathway (Figure 2, middle).
In addition, a knockin mouse model
with mutations of AMPK-targeted phos-
phorylation sites in acetyl-CoA carbox-
ylase 1 and 2 exhibited insulin resistance
and increased hepatic glucose produc-
tion (Fullerton et al., 2013). Importantly,
metformin treatment did not improve
high-fat-induced hyperglycemia in this
model, suggesting that phosphorylation
of acetyl-CoA carboxylase by AMPK
plays an important role in the alleviation
of hyperglycemia by metformin, perhaps
directly or through a reduction in hepatic
steatosis leading to improved insulin
sensitivity. Studies in humans also impli-
cate the LKB-AMPK pathway as central
to metformin action. Investigators from, February 3, 2015 ª2015 Elsevier Inc. 159
Figure 1. Pharmacokinetics of Metformin
After oral administration, metformin is absorbed by enterocytes in the intestine and delivered to the liver
through the portal vein. Metformin concentrations in the portal vein are 40–70 mM.Metformin is not metab-
olized in hepatocytes, and is eliminated by the kidney unchanged.Metformin can also be secreted into bile
through MATE1 transporter on hepatocytes.
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that AMPK subunits and LKB genes
were associated with a clinical response
to metformin, supporting the importance
of the AMPK pathway in the therapeutic
response to metformin in humans (Ja-
blonski et al., 2010).
In contrast, high metformin concentra-
tions (5 mM) have been proposed to
inhibit the respiratory chain complex 1 in
intact hepatocytes, leading to an increase
in the AMP/ATP ratio (El-Mir et al., 2000).
Based on this study and others, an
AMPK-independent pathway of metfor-
min suppression of glucose production
was proposed (Foretz et al., 2010). Foretz
et al. suggest that high metformin con-
centrations (R250 mM) lead to a decrease
in ATP levels and an increase in the AMP
levels, which then directly suppress
gluconeogenesis even in the absence of
AMPK. It should be noted, however, that
PCK1 protein levels were very low in
primary hepatocytes from AMPKa1/2
knockout mice compared to wild-type
control mice after metformin treatment
(Foretz et al., 2010), yet there were no
changes in Pck1 mRNA levels during the
same treatment paradigm in AMPKa1/2
knockout mice. These data suggest that
the high-concentration metformin effect
may be mediated by a change in protein
translation, which might have resulted
from a non-specific effect of the drug. In
contrast, low concentrations of metformin
clearly suppress Pck1mRNA levels in pri-
mary hepatocytes, and this effect is lost
after acute AMPKa1/2 depletion by
adenoviral shRNAs (Cao et al., 2014).
Presumably, low energy charge could
also suppress gluconeogenesis, without160 Cell Metabolism 21, February 3, 2015 ª2changing gluconeogenic enzyme ex-
pression, by activating the competing
pathway: hepatic glycolysis. However, it
is worth mentioning that at least 500 mM
metformin was required to suppress
hepatic gluconeogenesis by 50%, and
2 mM metformin was necessary to
maximally elevate the AMP/ATP ratio
(Foretz et al., 2010). As noted above, how-
ever, low metformin concentrations are
able to suppress glucose production in
primary hepatocytes without changing
either ATP levels or the AMP/ATP ratio
(Cao et al., 2014). In fact, we observed
an increase in hepatocyte ATP levels
with treatment at low metformin concen-
trations, which might be due to the activa-
tion of AMPK that then functions to
elevate the cellular energy charge,
perhaps by stimulating fatty acid oxida-
tion and inhibiting gluconeogenesis.
Other groups have also reported a phar-
macologic effect of metformin in rodent
models without altering mitochondrial
complex 1 activity (Madiraju et al., 2014).
In fact, very high concentrations of met-
formin in vitro (5 mM) are required to
observe a significant inhibition of complex
1 activity.
Foretz et al. also simultaneously treated
primary hepatocytes with metformin and
a cAMP analog to study the suppression
of glucose production (Foretz et al.,
2010). However, in clinical practice, met-
formin is generally taken with food in the
evening to control morning fasting blood
glucose levels. Metformin, therefore, rea-
ches its peak plasma concentrations well
before any elevation in blood glucagon
levels has occurred. We found that treat-
ment with metformin prior to the addition015 Elsevier Inc.of cAMP led to a greater suppression of
glucose production and AMPK activation
when compared to the simultaneous
treatment of metformin and cAMP (Cao
et al., 2014), suggesting that the cAMP-
PKA pathway may exert a negative effect
on AMPK activation. Indeed, mutation of a
PKA phosphorylation site on AMPKa1
(Ser485Ala) increased both AMPKa1
phosphorylation at Thr172 and suppres-
sion of glucose production in primary
hepatocytes treated with metformin
compared to wild-type hepatocytes.
Given that one-third of diabetic patients
either lack or have a delayed response
to metformin treatment, this interaction
of two signaling pathways has important
clinical implications for metformin usage
in diabetic patients with differing degrees
of hyperglucagonemia.
Expanding on the inhibition of mito-
chondrial respiratory chain complex 1 hy-
pothesis, Birnbaum’s group proposed
that elevated AMP levels suppress hepat-
ic glucose production through inhibition of
cAMP production by adenylyl cyclase
(Miller et al., 2013). However, in their
studies of primary hepatocytes, cellular
cAMP levels were only significantly
decreased at R 250 mM metformin; yet
they achieved a complete reduction in
glucose production in hepatocytes at
125 mM metformin, and we found that
even lower concentrations of metformin
are also effective in suppressing hepato-
cyte glucose production (Cao et al.,
2014). Since these supra-pharmacologic
concentrations of metformin are un-
achievable in the portal vein (>80 mM),
they may be clinically irrelevant and could
be perhaps toxic. Finally, we and others
find that metformin is still able to
inhibit glucose production stimulated by
dibutyryl-cAMP, a hydrolysis-resistant
cAMP analog (Foretz et al., 2010; Cao
et al., 2014), which is inconsistent
with the cAMP hypothesis. Miller et al.
also demonstrated inhibition of hepato-
cyte glucose output stimulated by a
hydrolysis-resistant cAMP analog at
500 mM metformin, but attributed the
effect to a non-specific effect of the
drug. Collectively, these findings sug-
gest that inhibition of adenylyl cyclase
is unlikely to explain the pharmaco-
logic action of metformin in man (Figure 2,
left).
Recently, Shulman’s group proposed
that metformin inhibits the enzymatic
Figure 2. Proposed Models for the Suppression of Glucose Production by Metformin
Model 1(left): Supra-pharmacologic metformin concentrations suppress glucose production through the
inhibition of complex 1 in mitochondria, which increases AMP levels and subsequently blocks the cAMP-
PKA pathway by the inhibition of adenylyl cyclase activity. Elevated AMP levels could also activate AMPK.
Model 2 (middle): Pharmacologic metformin concentrations, found in the portal vein, activate AMPK,
which inhibit gluconeogenic gene expression by phosphorylation of CBP and CRTC2. Model 3 (right):
Pharmacologic metformin concentrations inhibit mitochondrial glycerol 3-phosphate dehydrogenase,
leading to an increase in cytosolic NADH levels, which prevents lactate utilization and decreases gluco-
neogenesis. However, NADH is also consumed in gluconeogenesis at the GAPDH enzymatic step. It
has been reported that glycerol 3-phosphate dehydrogenase 2 (mitochondrial isoform) is negatively regu-
lated by AMPK through phosphorylation in yeast; however, this has not been demonstrated in mammalian
cells.
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phate dehydrogenase, which reduces
glucose production from both glycerol
and lactate (Madiraju et al., 2014). Baur
and Birnbaum, in an editorial, however,
raised several questions about this mech-
anism. First the glycerophosphate shuttle
is quantitatively much less important in
hepatocytes than the malate-asparate
shuttle and contributes very little to ATP
production (0.5%). Second, disruption
of the glycerophosphate shuttle in mice
is reported to have no effect on glycemia.
Third, gluconeogenesis from lactate
would be predicted to be unaffected,
since the NADH generated in the conver-
sion of lactate to pyruvate would subse-
quently be consumed by GAPDH in the
gluconeogenic pathway (Baur and Birn-
baum, 2014). Finally, a rapidly acting
parent compound of metformin (galegine)
in mice was used to model metformin ac-
tion in humans. However, galegine was
administered intravenously and would be
predicted to accumulate in blood at high
concentrations, which is inconsistentwith the pharmacokinetics of metformin.
By extension, a potential acute effect of
metformin, which is suggested by the
galegine data, does not match the clinical
effect of the drug, where improvement in
hyperglycemia in patients with type 2 dia-
betes is seen only after several weeks of
treatment. Thus, the acute galegine effect
could be different from the known chronic
effect of metformin, and models based on
galegine may be irrelevant or erroneous
when applied to metformin.
We suggest that the effect of metformin
in humans can be instructive in devel-
oping a model to explain its mechanism
of action. For example, Miller et al.
(2013) used phenformin, not metformin,
in most of their studies, noting that this
drug, with increased lipid solubility, is a
more effective inhibitor of complex 1 of
the electron transport chain. For the
same reason, phenformin is about 20
times more likely to cause lactic acidosis
in man and has been banned for human
use in most countries worldwide. In the
same way that cellular anoxia blocks theCell Metabolism 21electron transport chain and causes lactic
acidosis, inhibition of the electron trans-
port chain and ATP production is much
more likely to explain the toxicity of phen-
formin, and to a lesser extent metformin,
than it is to explain its mechanism of ac-
tion. An alternative hypothesis by Madir-
aju et al. (2014) suggests that a change
in cellular redox potential, not energy
charge, explains metformin’s mechanism
of action. Central to this hypothesis is that
both lactate and glycerol metabolism to
glucose in the liver is impaired and these
metabolites subsequently accumulate in
the plasma. Again, this does not match
the reported effect of metformin in hu-
mans with type 2 diabetes where lactate
levels and clearance are unaffected after
a 4 month treatment protocol (Stumvoll
et al., 1995). In fact, lactate oxidation
actually increases in diabetic patients
treated with metformin.
High metformin concentrations (doses)
are widely employed in animal and
in vitro studies, including some of our
own studies (He et al., 2009; Foretz
et al., 2010; Miller et al., 2013). Given the
known biological effect of low concentra-
tions of metformin (Cao et al., 2014), we
suggest that studies using high concen-
trations of metformin might actually
mask the AMPK-dependent pathway.
Interestingly, AMPK also phosphorylates
and negatively regulates the activity of
glycerol 3-phosphate dehydrogenase 2
in yeast, which is the analog of mammal
mitochondrial glycerol 3-phosphate de-
hydrogenase (Figure 2, right). This sug-
gests a possible interaction between a
pathway that regulates the activity of
mitochondrial glycerol 3-phosphate de-
hydrogenase and a direct effect of metfor-
min on AMPK (Lee et al., 2012). Since
large doses of metformin are given to pa-
tients with type 2 diabetes, its cellular
sites of action are likely to be many, and
pharmacologically relevant studies in the
future will be very important in separating
a mechanism of action from a non-spe-
cific or toxic effect.
Finally, it remains unclear how AMPK is
activated by metformin. As the activity of
upstream AMPK kinase (LKB1) is consti-
tutive, one possibility is that metformin
maymediate AMPK activation by promot-
ing the binding of LKB to AMPK. Another
possibility is that metformin may lead to
a conformation change in AMPK that fa-
cilitates AMPK activation by AMP/ADP,, February 3, 2015 ª2015 Elsevier Inc. 161
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unit is necessary for AMPK activation
(Hawley et al., 2010). Clearly, more work
needs to be done to uncover the mecha-
nism of AMPK activation by metformin.
We apologize to colleagues whose
work cannot be cited because of space
limitations.
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